As intrathecal delivery of the AON nusinersen is used for treatment in SMA, and we observed that systemic AON treatment was able to rescue retinal vascularity in SMA mice, we next set out to investigate whether AON treatment was able to rescue SMA-associated vasculopathy in vitro. This evidence concerns the gene SMN1 and proximal spinal muscular atrophy.